1.0
Jun 2, 2010
Anonymous employee
Current employee
Recommend
CEO approval
Business outlook
Pros
the things that are left are still valuable (but doubtless outsourced soon) it's not as bad as other pharma atm you can still get science done if you try
Cons
everything is done to a cost, regardless, and you get what you pay for people are waiting for a payout success in spite of not because of